Yung Shin Pharmaceutical Ind. Co., Ltd.

Sterling Winthrop Inc.

Anderson C Hong

Fang-Yu Lee

Ming-Liang Lee

David M Sedlock

Colin J Barrow

James E Brownell

David R Houck

Schung-Ching Chiu

Janet L Popp

The present invention provides two new microorganism strains of, designated as YS-44442 and YS-45494, a process of producing pravastatin using the strains, and an improved process for isolation of (HMG)-CoA reductase inhibitors.

[object Object]

The present invention provides two new microorganism strains of Saccharothrix, designated as YS-44442 and YS-45494, a process of producing pravastatin using the strains, and an improved process for isolation of (HMG)-CoA reductase inhibitors.

Strains of saccharaothrix, process for producing pravastatin using the strains and isolation process of (HMG)-CoA reductase

A novel Aspergillus species, cyclic dimeric dipeptide derivatives which are biosynthetic products thereof and are useful as Substance P antagonists and therefore as analgesic and/or antiinflammatory agents, and a process for preparation of the biosynthetic products are disclosed.

Aspergillus species, cyclic dimeric dipeptide derivative substance P

Growing community of inventors

Taipei, Taiwan

Anderson C Hong